PepBank has 1 Crystagen study with results. It did not give Crystagen. Data as of 2026-10-30.
Searches 0 results and 2 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Sources describe Crystagen as synthetic Glu-Asp-Pro in the Khavinson bioregulator family. This record uses the all-L, free-acid EDP reference structure. Supplier identity statements connect this structure to the commercial name. They do not verify every product sold under that name. Chemical identity does not establish clinical benefit or a safe human dose.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
3 amino acids
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 3.55 · Net charge at pH 7.4: −2.06
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 1.00 |
| 1 | 1.00 |
| 2 | 0.96 |
| 3 | 0.61 |
| 4 | −0.72 |
| 5 | −1.78 |
| 6 | −1.98 |
| 7 | −2.02 |
| 8 | −2.20 |
| 9 | −2.72 |
| 10 | −2.96 |
| 11 | −3.00 |
| 12 | −3.00 |
| 13 | −3.00 |
| 14 | −3.00 |
3 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 23624313(opens in a new tab)
C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)OPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
1 of 2 studies has results (50%), published 2016. Top row: every study. Bottom row: studies with results about Crystagen (EDP), by class. The rows use different scales.
Studies2 in all, 2014 to 2016
Studies with results1 in all, 2016
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
2 studies match. Retracted studies are left out.
Showing 1 of 2 studiesquery qry_6f44b2aea330025998164f49
1 study
Not a test of Crystagen (EDP) alone · 2016
Khavinson et al. 2016Bulletin of experimental biology and medicinecited by 9
PMID 27909961DOI 10.1007/s10517-016-3596-7PUB-27909961
These studies name Crystagen (EDP) but give no result for it (for example, the results concern another peptide in the study).
PubMed tag: none · 2014
Сhervyakova et al. 2014Advances in gerontology = Uspekhi gerontologiicited by 1
PMID 28976144PUB-28976144
Page 1 of 1
Khavinson VK · Bulletin of experimental biology and medicine · 2016
Not a test of Crystagen (EDP) alone · 2 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | The cited Drugs@FDA search returned no matches for Crystagen, Glu-Asp-Pro or Kristagen. This limited search does not exclude approval under another name. Compounding status remains unresolved. | 22 Oct 2026 | api.fda.gov (opens in a new tab) |
| EU | EMA | The cited EMA dataset contained no matches for Crystagen, Kristagen or Glu-Asp-Pro. This limited search does not establish absence of every authorisation. EU national authorisations remain unchecked. | 22 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Status unknown The peptide is not named in the 2026 list. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | Note | Registered in Russia as a dietary supplement, not as a medicine. It is not approved as a medicine. Current supplement certificate RU.77.99.88.003.R.002096.08.25 of 2025-08-12 (earlier 77.99.23.3.U.9171.8.06), read from a copy of the supplement register (reestrinform.ru, accessed 2026-10-22). The manufacturer also lists it as a dietary supplement. No entry in the State Register of Medicines was found. | 22 Oct 2026 | reestrinform.ru (opens in a new tab) |
Reported effects from study results.
No study results yet
The doses that these studies used. They are not recommendations.
No dose was reported in the study results.
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Crystagen (EDP): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
Outcome groups with study results, by evidence class.
No study results yet
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
No study results yet
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.